# TISSUEPAPER

# Histotechnology Group of Queensland

#### PRESIDENT'S REPORT - MARK BROMLEY

Welcome to our winter 2023 edition of TissuePaper.

I see myself write the word "winter" but let's face it, winter really isn't winter at all up in Queensland! We're the envy of every other state with our blue sunny skies.

Unfortunately, a last minute change of seating policy at our usual scientific meeting venue left us homeless for our last meeting, and despite a frantic scramble for an alternative venue, we were forced to abandon it. We will continue looking for alternatives, but for now the Pineapple Hotel in Kangaroo Point has thrown us a lifeline for the joint AIMS/HGQ meeting on the 24th of August. The topic is Forensics, so put it in your diaries!

Another date for the diary is the upcoming trivia night on Friday 28th of July, again at the Pineapple Hotel. Only a few weeks to go, so get your table booked and your brains in high gear for what I'm sure will be an evening of fun and frolics.

In This Issue:
President's Report: Mark Bromley
Out Damned Spot
HGQ Trivia information
Scientist focus
Save the date



And then, as if trivia isn't enough to stoke the flames of inter-lab rivalry, we have our inaugural axe throwing competition on Saturday September 2<sup>nd</sup> in Newstead. This will be a LOT of fun!

Please also join me in congratulating Kailan Bilney, who won the Histotechnology Group of Queensland QUT Award for the highest academic results in the third year Bachelor of Medical Laboratory Science Histology unit.

So until the next edition, enjoy the fabulous winter sun, unless you're one of our interstate readers, in which case stay warm!

NEW CAMERA 20.1 Mega Pixels 30x Optical Zoom



# The Perfect Match MacroPATH & LOOX

The new Milestone **MacroPATH** boasts a 20.1 megapixel camera and assures improved productivity and workflow for the grossing room.

Quality of images is optimized and the software is user friendly and icon-driven for easy operation.

In addition to stand-alone operation, the MacroPATH can interface to your LIS. No more hand drawing and long descriptions!

#### The Perfect Match: MacroPATH + LOOX



LOOX Eye-Control is the Milestone solution engineered for enhancing comfort while carrying out **hands-free gross specimen** documentation during pathological dissection.

The perfect combination **LOOX + MacroPATH** facilitates pathologists in display, manipulation and analysis of the grossing step; allowing them to take pictures and record audio and video, with the most intuitive and efficient visual control.





Distributed by Abacus dx - Contact Andrew for a quote Andrew Engel Territory Manager- QLD & NT 0483 375 091 | a.engel@abacusdx.com | www.abacusdx.com

### abacus d×

# **Committee Members**

Role	Name	Company
President	Mark Bromley	SNP
Secretary	Amanda Marsden	PQ-PAH
Trade	Samantha Arandelovic	MATER
Treasurer	Samantha Arandelovic	MATER
Newsletter	Kim Judge	TRADE
Newsletter	Sharee Durdin	MATER
Newsletter	Courtney Colless	TAFE QLD
Newsletter	Christopher Boyle	PQ-RBH
Newsletter	Cally Matthews	SNP
Social Events	Emma Hughes	SNP
Workshops	Chris Cazier	QUT
Workshops	Maddison Burrowes	QUT
Scientific Meetings	Brett Harrison	TRADE
Website	Maddison Burrowes	QUT
Social Media	Maddison Burrowes	QUT

Follow Histotechnology Group of Queensland: https://www.facebook.com/histo.group.qld

https://www.instagram.com/histogrpqld/ https://www.linkedin.com/company/histotechnology-group-of-queensland/

Contact us at: General: <u>https://www.hgq.org.au/</u> Newsletter: <u>newsletter@hgq.org.au</u> Trade: <u>trade@hgq.org.au</u>







# HistoBond<sup>®</sup> adhesive slides

#### Histobond®+

HistoBond®+ slides are suitable for immunohistochemistry and in situ hybridization. Tissue sections are bonded by a positive charge to the slide.

These slides have a white or coloured printed area for notes and labelling, suitable for automated systems.

#### Histobond®+S

HistoBond®+S microscope slides offer a considerably higher positive charge. This improves the adhesion of the tissue sections to the glass even under less favorable conditions, e.g. when using alkaline reagents.

#### **Superior Marienfeld**

Made in Germany, stocked in Australia

Contact us for free samples to trial

#### Also in our Marienfeld range: Coverslips

- round, square or rectangular
- chemically-resistant borosilicate
- 2-part boxes or hinged lid boxes
- thickness Nos. 0, 1, 1.5, 1.5H, & 2
- automatic coverslipper approved

Microscope slides

- plain or frosted
- flat or with up to 3 cavities
- cut edges or 90° ground edges
- 90° or 45° corners

VISIT OUR WEBSTORE

ENQUIRE VIA EMAIL

sales@southerncrossscience.com.au



Lab Equipment & Furniture | Cleanroom Products | Plasticware | Chemicals | Glassware | Safety Products | Servicing & Installation | Lab Fit-Outs & Construction | Fume Cupboards

#### LEICA BIOSYSTEMS

# HISTOCORE MICROTOME RANGE

NEW! HISTOCORE WATER BATH AND SLIDE DRYER

#### LIMITED TIME OFFER!

To Celebrate the release of the new HistoCore Water Bath and Slide Dryer Leica Biosystems is proud to introduce a limited introductory offer:

For a limited time, receive a **New HistoCore Waterbath and Slide Dryer at no charge** with the purchase of any instrument from the HistoCore microtome range!

#### Offer is valid to August 31, 2023.



#### CONTACT YOUR LOCAL LEICA BIOSYSTEMS SALES REPRESENTATIVE TODAY!

TERMS AND CONDITIONS:

This offer cannot be used in combination with any other Leica Biosystems discounts or promotional offers, two dryer option also available, please consult your sales representative. This offer expires August 31, 2023. Offer valid in Australia and New Zealand only

#### Advancing Cancer Diagnostics Improving Lives



FOR IN VITRO DIAGNOSTIC USE

Copyright @ 2022 Leica Biosystems, a division of Leica Microsystems Inc. All Rights Reserved. LEICA and the Leica logo are registered trademarks of Leica Microsystems IR GmbH

230477 Rev A • 05/2023

#### **Publication Guidelines**

Material in this Newsletter may be copied for personal use only and not for commercial gain. Both the Author and permission to copy must be acknowledged. No responsibility is assumed by the Histotechnology Group of Queensland Incorported or the Editorial Committee for any injury and/or damage to persons or property as a matter of producut liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, ideas contained in this Newsletter. It is the user's responsibility to ensure that all procedures are carried out in accordance with all relevent Health and Safety requirements. Any opinions expressed are those of the contributors and and not necessarily those of The Histotechnology Group of Queensand or the Editoral Committee.

#### Newsletter correspondence

For all newsletter correspondence please email: newsletter@hgq.org.au

#### **Guidelines to Contributors**

Please forward submissions in .docx or .pdf via email to: <u>newsletter@hgq.org.au</u>. For any attached photos, please also include these in a separate file. Include your name and address if required. Submissions can be in the form of a brief note, letter, or as a complete article.

#### Advertisement rates

Single A4 page - \$200

Please provide a copy of advertisement(s) in digital formats (as prescribed above) only. All monies payable to: HISTOTECHNOLOGY GROUP OF QUEENSLAND

# **Out Damned Spot**

Article from the Registrars presentations given at the Mater Hospital Anatomical Pathology Dept.

Dr. Shelley Verma, 04/04/2023 Article summary taken from the presentation given by Dr Verma.

Firstly, Shelley took time in outlining the talk and presented the following points.

Outline

- Meet the Melanocytic lesions
- Clinical Concern
- Histology
- Immunohistochemistry
- Molecular techniques
   A word on sentinel lymph nodes



Firstly, Shelly dived into the brief history of Melanoma, giving everyone a lesson in how long we humans have been aware of Melanoma and how our understanding has grown.

A brief history of melanoma

th

- First described by Hippocrates in the 5 century BCE
- Widely metastatic disease found in Peruvian mummies from 2400 years ago
- Given its name in 1838 (previously "fungous tumour") by Carswell
- The first melanoma to be surgically removed, in 1787, is preserved in a London Museum
- Also in the early 1800's:
- Mostly seen in pale skinned people
- Can be hereditary
- Only way to survive is to resect the disease early
- And so, it has remained, until 2011 when Immunotherapy became viable

# Experience the future of digital pathology







- Largest-capacity, whole-slide scanner on the market: 1000 standard-width slides
- Can scan 15x15 mm slide area in 30 seconds (40x resolution, 0.25 μm/pixel, single layer)<sup>1</sup>
- Touch-enabled, easy-to-use software interface
- Double-width slide capacity (optional)
- Flexible Priority/STAT slide position allocation

<sup>1</sup>Actual scanning time dependent on slide quality, local server speed and other factors

## Pannoramic 1000



When speed is your need. Free up your laboratory's resources with the new Pannoramic 1000 – the high-throughput whole-slide scanning solution.

- Parallel operation: slide loading and preview in parallel with scanning
- Three individual objectives exchangeable automatically during scanning
- Multilayer (Z-stack) and Extended Focus scanning (optional)
- 1D and 2D barcode reading and parsing
- Automated tissue detection and coverslip detection



Bio-Strategy PTY Limited T 1800 00 84 53 | <u>sales.au@bio-strategy.com</u> <u>www.bio-strategy.com</u> | <u>shop.bio-strategy.com</u>



#### **Other Dates**

- Anaesthesia was invented in 1846
- Antisepsis first used in 1865
- Hereditability Mendel published in 1865
- DNA discovered by Miescher in 1860

Back to present Day!

- Melanoma is the 10<sup>th</sup> most common cause of cancer death
- #19 in top 20 causes of death in Australians between 25-44 (young people!)
- 1400-ish people die of melanoma of the skin in Australia every year
- Or 6.4 people per 100 000



What Shelley described as Melanocytic Minions (lots of sub-groups of Melanocytic lesions) are laid out in the following tables.

As you can see there are heaps of groupings subsets.

#### 3. Melanocytic neoplasms

Introduction	Melanocytic tumours in acral skin
Genomic landscape of melanoma	Acral naevi
Melanocytic neoplasms in intermittently sun-exposed skin	Acral naevus
Naevi	Acral melanomas
Junctional, compound, and dermal naevi	Aaral malanama
Simple lentigo and lentiginous melanocytic naevus	Acrai melanoma
Dysplastic naevus	Genital and mucosal melanocytic tumours
Naevus spilus	Mucosal and genital naevi
Special-site naevi (of the breast, axilla, scalp, and ear)	Melanosis
Halo lidevus	Occitel accurate
Recurrent naevus	Genital naevus
Combined naevus	Mucosal melanomas
Melanocytomas	Mucosal melanomas
WNT-activated deep penetrating/plexiform melanocytoma (naevus)	Blue naevus and related tumours
Pigmented epithelioid melanocytoma	Dive recy and related tamours
BAP1-inactivated melanocytoma	Blue naevi and melanocytoses
MITF pathway-activated melanocytic tumours	Naevus of Ito and naevus of Ota
Melanoma intermittently sun-exposed skin	Congenital dermal melanocytosis
Low-CSD melanoma (including superficial spreading melanoma)	Blue naevus
Melanocytic neoplasms in chronically sun-exposed skin	Melanara arisin fara biya anari
Lentido maligna melanoma	meianomas arising from blue naevi
	Melanoma arising in blue naevus
Spitz tumours	Congenital melanocytic tumours
Spitz naevi	Congenital naevi
Pigmented spindle cell naevus (Reed naevus)	Congenitar naevi
Spitz naevus	Congenital melanocytic naevus
Spitz melanocytoma	Proliferative nodules in congenital melanocytic naevus
Spitz melanocytoma (Atypical Spitz tumour)	Melanomas arising in congenital naevi
Spitz melanoma	Melanoma arising in giant congenital paevus
Spitz melanoma	melanoma ansing in giant congenital haevus

#### **Clinical Assessment**

This portion of Shelley's talk related to the presentations of Melanoma and "pre-Melanoma" – Melanocytic lesions. See the below images of some textbook presentations of Nevi.

These images demonstrate just how varied they present on our skin. And also, just how important it is to have an expert check your skin for these types of lesions.



Dr Verma stressed the importance of having checks, and having your skin checked regularly.

Agilent

HGQ

**Third Edition** 

## Precision Oncology Summit 2023 Available On-Demand

Designed for researchers, clinician-scientists, pathologists, industry professionals, and interested individuals, the summit offers the latest market trends and updates in the developing field of precision oncology.

Over 900 participants have benefited from this series of educational summits. Don't pass up this exciting chance to learn!

Available on-demand from 1 June to 30 June 2023.



PR 7001-0906 © Agilent Technologies, Inc. 2023



#### DERMOSCOPY

The local doctor / GP skin clinic and specialised dermatologist will enlist these devises to visualise, measure and record their patients' lesions. All are very important tools that everyone's GP or health provider can utilise to help detect melanocytic lesions early.

- Dermoscopy uses a hand-held magnifier with a light source, ideally polarised, to allow the practitioner to see into the skin
- Fancy ones have cameras and mapping software
- Basic ones come as an iPhone attachment



#### What you typically expect to see from a Melanocytic Lesion?

- A Asymmetry of shape and colour
- B Border: irregular, ill-defined, smudgy
- C Colour variation or change
- D Different the ugly duckling sign
- E Evolving or Elevated
- F Firm to touch



# The ONE Leading Assay with KEYTRUDA®

#### Available for Triple-Negative Breast Cancer (TNBC) in Australia

Used in the KEYNOTE-355 clinical trial, PD-L1 IHC 22C3 pharmDx (SK006) is the companion diagnostic test that can help identify TNBC patients for treatment with KEYTRUDA (pembrolizumab). When confidence in a PD-L1 test is critical, the ONE you choose is crucial.

Pursue lab excellence with the leading PD-L1 assay for KEYTRUDA.

THIS PRODUCT IS NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.

KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Review the PD-L1 IHC 22C3 pharmDx Instructions for Use for more information regarding the KEYNOTE clinical trials

D75941\_01 © Agilent Technologies, Inc. 2023





#### See below examples







# **HURST** SCIENTIFIC

The fully automatic sectioning device is capable of cutting up to 96 paraffin blocks as well as delivering 400 sections mounted on slides, registered, dried and ready for further analysis.

All in just 4-6 hours – and without the intervention of a user along the way, which gives a crucial capacity boost to the laboratory.

#### The goal is improved diagnostics

In fact, quality is the core focus of the machine. The AS-410M is equipped with an advanced precision microtome and has automatic blade replacement along the way.

All blocks are measured and adjusted automatically so that they are optimally angled in relation to the microtome knife. The cutting takes place with precise timing at a controlled temperature, which gives cuts with very high uniformity. In addition, the machine can



be set to detect the surface photographically, so that the cuts are cut with the largest possible tissue surface in the block. The result is an extremely high cut quality that creates the perfect starting point for analysis and diagnostics.



#### State-of-the-art microscopes for advanced Life Science applications

The outstanding optical performance of the Delphi-X Observer<sup>™</sup> with 25 mm fields of view and high numerical aperture of the Plan 60 mm parafocal EIS objectives enables perfect observations and color rendering at high resolving power. This is the perfect microscope for anatomo-pathologists

- Trinocular model
- Sextuple reversed nosepiece with slot for optional DIC prism(s)
- Super Wide field SWF 10x/25mm eyepieces, Ø 30 mm tubes
- Enhanced infinity corrected EIS optical system
- Ergonomic tilting head
- 60 mm parafocal Plan EIS objectives
- 60 mm parafocal Plan Semi-Apochromatic EIS objectives
- 3 W NeoLED<sup>™</sup> illumination
- 100 W halogen illumination
- Face-to-face dual head system
- Multihead systems
- Motorized versions
- Medical device class I



#### www.hurstscientific.com.au

Here we have some more detail on what our physician/s look for with assessing the lesions they are presented with.

The Nature of Pigmented Lesions

- Dysplastic naevus
  - Usually has a junctional and a dermal component
  - Should have architectural and cytological atypia
  - But not as much as melanoma

Architectural features

-Nests part way up rete ridges

- -Bridging of adjacent rete
- -Upwards scatter of melanocytes
- -Increased density of non-nested melanocytes

Cytological features

- -Nuclear size larger than keratinocyte
- -Hyperchromatism, coarse chromatin
- -Nuclear pleomorphism
- -Nucleoli prominent/lavender



Other Clues for Melanoma

Lack of maturation A cytologically distinct population within a naevus Intra-epidermal or intradermal mitotic figures Especially at the leading/deep edge Ulceration Destruction of adnexal structures Large size Histologically asymmetrical Infiltrating lymphocytes

#### Below images of architectural and cytological features





Then Dr Verma discussed the use of the important and highly useful tool "Immunohistochemistry" and how we utilise panels of Antibodies to indicate positive and neg staining and what these can indicate.

#### mmunohistochemistry

SOX10 – to highlight Pagetoid spread HMB45 – tends to be lost with maturation (so will fade with depth in benign naevi) The malignant cocktail

- P16 (looking for loss)
- Ki67 (expect <5% within dermal nests)</li>
- PRAME

#### The New Kid on the Block – PRAME

PRAME was initially identified as a target antigen on tumor specific lymphocytes in a patient with metastatic melanoma

IHC was initially developed to select potential cases for immunotherapy, NOT as a marker of malignancy The first PRAME paper aimed to validate the IHC, use in determining malignant potential was a happy coincidence

ORIGINAL ARTICLE

PRAME Expression in Melanocytic Tumors

Cecilia Lezcano, MD,\* Achim A. Jungbluth, MD,\* Kishwer S. Nehal, MD,† Travis J. Hollmann, MD, PhD,\* and Klaus J. Busam, MD\*



#### Graph of PRAME specificity for the different tumours

BUT !! (why is there always a but)

Not as good in histologically ambiguous lesions Only weak to moderate agreement with well-validated molecular tests in this setting

#### PRAME

Interpretation: any nuclear positivity in >75% of lesional cells (original described cut off point) Usage:

In small melanomas arising within naevi (to show a distinct population)

In lesions too superficial for molecular analysis

In distinguishing nodal mets from nodal naevi (near 100% sensitive and specific in this circumstance) Margin assessment in known PRAME positive melanomas

CAUTION - isolated PRAME positive cells are often seen in severe sun damaged skin

Then Dr Verma moved into the Molecular Genetics techniques we can use to help identify the precursor subtypes, see below for some tables and descriptions of molecular techniques.

MOLECULAR TECHNIQUES

For determining melanocytic lesion subtype

For assessing malignant potential

CGH

FISH

Next Dr Verma described the differences of her Melanocytic minions with molecular alterations.

Molecular hallmark						
Lesion type	Molecular hallmark	Technique				
Spitznaevus	ALK fusion ROS fusion NTRK fusion	IHC and FISH				
Deep penetrating naevus	CTNNB1 mutation (B catenin)	IHC				
BAP1 inactivated melanocytic tumours	BAP1 mutation	IHC				
Blue naevus spectrum	GNAQ, GNA11 activating mutations	NGS IHC (NEGATIVE for BRAFv600e)				

ssessing malignant potential: A Caveat

Histology remains the gold standard for differentiating benign from malignant Most studies are done in definite benign v malignant tumours We need these tests for lesions with borderline histology None of the tests have been around long enough for long term follow up of borderline lesions.

#### CGH

Comparative Genomic Hybridisation

The principle

New kits analyse thousands of loci across the genome, output is mapped by chromosome

Deflection away from the baseline indicates loss or gain of allele

Gives both an indication of chromosomal instability but can also provide:

Information about specific cytogenetic abnormalities (eg: 11p gain in desmoplastic spitz naevus, ALK or ROS translocations in other spitz naevi)

Presence of specific mutations (homozygous deletion of CDKN2A is high risk for malignant behaviour even in the absence of other mutations)

Question for us;

How many copy number changes make malignancy? Sensitivity and specificity changes depending on cut offs



Figure 1. Typical SNP array output. The upper panel shows copy number status (log ratio on the vertical and chromosome locus on the horizontal). Gains and losses are reflected by deflections of the average yellow line above or below 0, respectively. Red arrow indicates a one copy number loss of chromosome 9p and black arrow a gain of chromosome 11p. The lower panel shows the B-allele frequency for each SNP on the array (B-allele frequency on the vertical and chromosome locus on the horizontal). In the normal state this track consists of three lines, a middle heterozygous line and two outer lines which are homozygous for the A and B alleles. Red and black arrows indicate LOH events on chromosomes 9p and 11p.

#### CGH V. MULTIPLEX FISH

Multiplex FISH targets a much more limited number of loci (most studies use 4, but up to 6). See number of signals per nucleus and ratio of signals.

Benefits of FISH	Downsides of FISH
Requires fewer cells	Less sensitive and specific
Does not have a minimum tumour purity	Lower genomic coverage
Cheaper/more readily available	Cannot give specific mutations
Faster	Requires expertise to interpret

Molecular testing for melanocytic tumors 161



Figure 6. Algorithm for integrating histology with molecular data in the diagnosis of melanocytic tumors.

Then to wrap up Dr Verma's talk she led us to further discussions on Sentinel Lymph nodes.

And explained the importance of the sourcing and investigations of sentinel nodes in the patients journey from cancer sufferer to survivor.

#### Sentinel Lymph Nodes



#### Purpose of the Sentinel Node Biopsy

Mostly prognostication

A large randomised controlled trial showed no survival benefit or distant disease recurrence rate between groups with a positive sentinel node followed by regional nodal dissection and those who did not have a sentinel node biopsy performed Strongest predictor of melanoma specific survival Indicated if: Primary melanoma >1mm thickness Clinically node negative

#### What guidance do we have?

There is no consensus on how to cut sentinel nodes, how many H&E sections to make, at what interval or what IHC should be used

Australian guidelines suggest:

Bivalve along longitudinal axis or breadloaf

"Pathologists should examine multiple haematoxylin-eosin and immunohistochemically-stained sections from each SLN. Sections from each slice of all SLNs should be stained with both H&E and immunohistochemistry for melanoma associated antigens. HMB-45, S100, SOX10, Melan A and tyrosinase have all been utilised as immunohistochemical stains." Here's some guidance from the European Organisation for Research and Treatment of Cancer (EORTC) Comparison Trail In the trial: Bivalve the node longitudinally 10 sections of each half S100, melanA, HMB45 In 2008: Bivalve longitudinally 4 sections Stain 1 and 4 with H&E

Stain 2 and 3 with S100 and HMB-45



#### ake Home Message

Melanocytic lesions are tricky for everyone Evidence is evolving!

#### If in doubt, cut it out!

Thanks to Dr Shelley Verma for supplying her presentation for the QLD Histotechnology Group to make into this article. Thanks to DermNet, ExpertPath and ihearthisto for the images used in this talk. References

- Andea A (2022) Molecular testing for melanocytic tumours: a practical update. Histopathology 80:150-165
- McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012;22(3):276-82.
- Lezcano, Cecilia, Jungbluth, Achim, Nehal, Kishwer, Hollmann, Travis, MD, PhD & Busam, Klaus. (2018). PRAME Expression in Melanocytic Tumors. American Journal of Surgical Pathology, 42, 1456-1465.
- Harvey, Nathan, Peverall, Joanne, Acott, Nathan, Mesbah Ardakani, Nima, Leecy, Tamazin, Iacobelli, Jean, et al. (2021). Correlation of FISH and PRAME Immunohistochemistry in Ambiguous Superficial Cutaneous Melanocytic Proliferations. American Journal of Dermatopathology, 43, 913-920.
- Lohman, M. E., Steen, A. J., Grekin, R. C., & North, J. P. (2021). The utility of PRAME staining in identifying malignant transformation of melanocytic nevi. *Journal of cutaneous pathology*, 48(7), 856–862.
- Cancer council, Clinical Guidelines When is sentinel lymph node biopsy (SLNB) indicated?
- https://wiki.cancer.org.au/australia/Clinical question:When is a sentinel node biopsy indicated%3F
- Rebecca VW, Sondak VK, Smalley KS. A brief history of melanoma: from mummies to mutations. Melanoma Res. 2012 Apr;22(2):114-22. doi: 10.1097/CMR.0b013e328351fa4d. PMID: 22395415; PMCID: PMC3303163.
- Cochran AJ, Wen DR, Huang RR, Abrishami P, Smart C, Binder S, Scolyer RA, Thompson JF, Stern S, Van Kreuningen L, Elashoff DE, Sim MS, Wang HJ, Faries MB; MSLT-I Study Group. Sentinel lymph node melanoma metastases: Assessment of tumor burden for clinical prediction of outcome in the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Eur J Surg Oncol. 2022 Jun;48(6):1280-1287. doi: 10.1016/j.ejso.2022.01.021. Epub 2022 Feb 12. PMID: 35246348.

# Put a lab team together and bring out your inner WKING





Maniax Axe Throwing Newstead 52a Doggett St, Newstead.

https://www.maniax.com.au/



Please transfer payment to: Histotechnology Group of Queensland Inc, BSB 084 009 A/c 198048439

Email: <u>secretary@hgq.org.au</u> with your team name, members and payment details.

#### Saturday 2<sup>nd</sup> September





We are getting together in-person again! Join us for

# **Histo at the Beach**

#### Saturday 29th July 2023

First presenter announced: 'Forensics on the foreshore' Dr Allan Cala, Forensic Pathologist, NSW Health Pathology

#### Get out and about! Face to Face 10am till 3.30pm

#### Don't forget the food! 2 course lunch & drinks





#### **Register now!**

https://histonsw.org.au/event/histo-at-the-beach/

Click here, use the QR code or visit our website to register!\*

Registrations close 17th of July 2023

# **Save the Date**

A COMBINED SCIENTIFIC MEETING BROUGHT TO YOU BY THE

HISTOTECHNOLOGY GROUP of QUEENSLAND & AIMS QUEENSLAND STATE BRANCH

#### Thursday 24th August 2023

The Plantation Room @ The Pineapple Hotel 706 Main St, Kangaroo Point QLD 4169

6.30pm - 8.30pm

#### RSVP by 22/8/2023 @ 3pm AEST

FREE for AIMS and HGQ members/student members







# **Contributions welcomed!**

Journal, scientific article and antibody reviews all accepted! Know someone who should be featured? Something exciting happening in your lab? Want to do a birthday shout out? Have a photo you want to share? Let us know!

We are always looking for contributions of scientific articles and news, or if you have improvements and techniques that make a difference in your lab!

Submissions can be sent to HGQ Tissue Paper in digital format







